Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899786 | 0.82 | MAPT (0.42) | MEN1KMT2AHSP90AA1 | |
| SCHEMBL903020 | 0.76 | NPC1 (0.37) | MEN1KMT2ANUDT1BACE1HSP90AA1 | |
| SCHEMBL899736 | 0.75 | MEN1 (0.48) | MEN1KMT2ANUDT1BACE1HSP90AA1 | |
| SCHEMBL899717 | 0.74 | NUDT1 (0.34) | MEN1KMT2ANUDT1BACE1HSP90AA1 | |
| SCHEMBL278752 | 0.73 | NUDT1 (0.37) | NUDT1BACE1HSP90AA1 | |
| SCHEMBL899009 | 0.72 | ESR1 (0.33) | MEN1KMT2AKCNQ3KCNQ2 | |
| Phenol SCHEMBL8777717 | 0.72 | NUDT1 (0.35) | MEN1KMT2ANUDT1BACE1HSP90AA1 | |
| SCHEMBL3364355 | 0.72 | NUDT1 (0.39) | MEN1KMT2ANUDT1BACE1HSP90AA1 | |
| SCHEMBL8910722 | 0.71 | NUDT1 (0.39) | NUDT1BACE1HSP90AA1 | |
| SCHEMBL757158 | 0.70 | NUDT1 (0.37) | MEN1KMT2ANUDT1BACE1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530133-B2 | Preparation of norbornane-based PAC ballasts | PROMERUS, LLC (US) | 2013-09-10 | — | — | US | disclosed |
| EP-2622410-A1 | NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC | Promerus, LLC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | PROMERUS LLC (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012044719-A1 | NORBORNANE-BASED PAC BALLAST AND POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PAC | PROMERUS LLC (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | NBAS, PHB2, BDNF | MEN1 2147/4885KMT2A 701/4885KCNQ3 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.